肝癌椎管内硬脊膜外转移1例

2020-02-12 缪逸涛 杨军 陈庚 中国临床神经外科杂志

男,43岁,因胸背部持续性刺痛2个月加重10 d,伴双下肢无力、麻木逐渐加重、大小便功能障碍5 d入院。既往肺结核病史20年,乙型病毒性肝炎病史10年。入院前10 d当地县医院肺部CT检查示双肺上叶、右肺下叶陈旧性结核;胸8椎体水平椎管内异常稍高密度影。

1.病例资料
 
男,43岁,因胸背部持续性刺痛2个月加重10 d,伴双下肢无力、麻木逐渐加重、大小便功能障碍5 d入院。既往肺结核病史20年,乙型病毒性肝炎病史10年。入院前10 d当地县医院肺部CT检查示双肺上叶、右肺下叶陈旧性结核;胸8椎体水平椎管内异常稍高密度影。
 
入院时体格检查:第7、8胸椎棘突及椎旁压痛、叩击痛,双下肢肌力0级,肌张力降低;脐平面以下皮肤痛、温觉减退。入院后胸椎MRI检查示:胸7、8椎体水平椎管内硬脊膜外大小约3.5 cm×3.0 cm×2.0 cm等T1、稍长T2信号影(图1A、1B),增强扫描呈较均匀明显强化,边界欠清,部分延伸至胸7~8左侧椎间孔并侵蚀部分骨质,相应水平脊髓明显受压前移(图1C、1D),胸3、8、9椎体内见斑片状等T1、等T2信号影(图1A、1B),增强扫描呈较均匀明显强化(图1C)。术前诊断:胸7、8椎体水平椎管内硬脊膜外占位性病变,考虑恶性可能。





图1A~D. 术前MRI,可见胸7、8椎体水平椎管内硬脊膜外大小约3.5 cm×3.0 cm×2.0 cm等T1、稍长T2信号影,增强扫描呈较均匀明显强化,边界欠清,部分延伸至胸7~8左侧椎间孔并侵蚀部分骨质,相应水平脊髓明显受压前移;
 
术前门冬氨酸氨基转移酶65.4 U/L,丙氨酸氨基转移酶96.1 U/L,乙肝表面抗原阳性。全麻下行后正中入路椎管内占位切除术。超声骨刀整块打开椎板后,见灰褐色肿瘤位于胸7、8椎体椎管内硬脊膜外并有部分沿左侧椎间孔侵及椎管外,脊髓明显受压被推向右前方。肿瘤血供丰富,质地中等,边界欠清。术中行神经电生理监测,显微镜下整块切除肿瘤及受侵硬脊膜、椎骨。
 
术后病理示:转移性腺癌,结合免疫组化结果考虑肝脏来源。术后肺部CT及甲状腺超声检查未见原发或转移病灶,肝胆胰脾CT增强示肝硬化、肝内多发占位性病变,考虑恶性病变,原发性肝癌可能性大。血清糖链抗原125 107.89 U/ml,甲胎蛋白719.63 ng/ml。术后胸背部刺痛感消失,术后1周时双下肢肌力1级,复查胸椎MRI证实肿瘤全切(图1E、1F)。出院后随访3个月,双下肢肌力3级,大小便功能障碍明显改善,但因家属放弃治疗,于出院后4个月死亡。


图1 E、F. 术后矢状位、轴位增强MRI,可见肿瘤全切
 
2.讨论
 
原发性肝癌通常经淋巴管向肝门周围的区域淋巴结转移,通过血行向远处转移,最常见的转移部位依次是肺、肾上腺、局部淋巴结和骨骼。但以脊髓压迫为首发症状的肝癌椎管内硬脊膜外转移较少见。其转移的机制可能如下:与脑转移或肺转移共存,经动脉途径播散;经椎静脉丛播散;经蛛网膜下腔播散;邻近病灶的直接侵入。本文病例胸椎MRI显示胸3、8、9椎体内亦存在异常信号影,不排除并存椎体转移的可能。椎管内肿瘤根据其定位分为三种:硬脊膜外、硬脊膜内髓外和髓内。但恶性转移通常多见于硬脊膜外。其症状由肿瘤进行性压迫脊髓及其神经根所致。初期特点为受压神经后根所支配的区域内出现神经根性疼痛或感觉异常。随着肿瘤快速生长、侵袭以及瘤周水肿、出血导致症状迅速加重,短期内即出现脊髓半侧损害综合征或不完全性截瘫并迅速进展至完全性截瘫。
 
本文病例满足以上临床特点,并存在长期乙型病毒性肝炎病史,肝功能异常,肝内多发占位且血清甲胎蛋白达719.63 ng/ml。提示如早期诊治,在神经根性疼痛发生时即行减压,可避免截瘫发生。本文病例存在肺结核病史,在诊断时亦需注意与脊柱结核相鉴别。原发性肝癌椎管内转移通常已是癌症晚期的表现之一,且家属多选择放弃治疗,故此类病人预后较差。但为减轻肝癌转移病人疼痛,提高总生存期内生活质量,及早发现脊髓压迫症状并给予姑息治疗是必要的。放疗时因局部正常脊髓需耐受与肿瘤相同的照射剂量,副作用较大,有加重原有功能障碍的风险。故一旦发现椎管内转移,应及早行手术以解除肿瘤对脊髓的压迫,挽救脊髓及神经功能。
 
原始出处:

缪逸涛,杨军,陈庚,洪新雨.肝癌椎管内硬脊膜外转移1例[J].中国临床神经外科杂志,2019,24(01):62-63.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=886243, encodeId=6b6288624382, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c305416237, createdName=ms2000001313681173, createdTime=Fri Sep 18 05:14:19 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690788, encodeId=cda21690e88f2, content=<a href='/topic/show?id=de3362880f1' target=_blank style='color:#2F92EE;'>#椎管内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62880, encryptionId=de3362880f1, topicName=椎管内)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6d29130493, createdName=bugit, createdTime=Fri Dec 11 23:35:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724270, encodeId=888c1e24270d4, content=<a href='/topic/show?id=71c1628e901' target=_blank style='color:#2F92EE;'>#椎管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62879, encryptionId=71c1628e901, topicName=椎管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d4e33593434, createdName=caobinglei8090, createdTime=Thu Jan 07 16:35:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380048, encodeId=821d3800481e, content=感觉这个术前没查清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de55206789, createdName=1474f4afm33暂无昵称, createdTime=Wed Mar 04 04:34:58 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515785, encodeId=a6a81515e8564, content=<a href='/topic/show?id=92ace361409' target=_blank style='color:#2F92EE;'>#硬脊膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73614, encryptionId=92ace361409, topicName=硬脊膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70110872610, createdName=ms7421025882867189, createdTime=Fri Feb 14 00:35:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040260, encodeId=256f104026067, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Feb 12 12:35:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-09-18 ms2000001313681173

    已读

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=886243, encodeId=6b6288624382, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c305416237, createdName=ms2000001313681173, createdTime=Fri Sep 18 05:14:19 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690788, encodeId=cda21690e88f2, content=<a href='/topic/show?id=de3362880f1' target=_blank style='color:#2F92EE;'>#椎管内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62880, encryptionId=de3362880f1, topicName=椎管内)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6d29130493, createdName=bugit, createdTime=Fri Dec 11 23:35:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724270, encodeId=888c1e24270d4, content=<a href='/topic/show?id=71c1628e901' target=_blank style='color:#2F92EE;'>#椎管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62879, encryptionId=71c1628e901, topicName=椎管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d4e33593434, createdName=caobinglei8090, createdTime=Thu Jan 07 16:35:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380048, encodeId=821d3800481e, content=感觉这个术前没查清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de55206789, createdName=1474f4afm33暂无昵称, createdTime=Wed Mar 04 04:34:58 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515785, encodeId=a6a81515e8564, content=<a href='/topic/show?id=92ace361409' target=_blank style='color:#2F92EE;'>#硬脊膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73614, encryptionId=92ace361409, topicName=硬脊膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70110872610, createdName=ms7421025882867189, createdTime=Fri Feb 14 00:35:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040260, encodeId=256f104026067, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Feb 12 12:35:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-12-11 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=886243, encodeId=6b6288624382, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c305416237, createdName=ms2000001313681173, createdTime=Fri Sep 18 05:14:19 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690788, encodeId=cda21690e88f2, content=<a href='/topic/show?id=de3362880f1' target=_blank style='color:#2F92EE;'>#椎管内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62880, encryptionId=de3362880f1, topicName=椎管内)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6d29130493, createdName=bugit, createdTime=Fri Dec 11 23:35:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724270, encodeId=888c1e24270d4, content=<a href='/topic/show?id=71c1628e901' target=_blank style='color:#2F92EE;'>#椎管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62879, encryptionId=71c1628e901, topicName=椎管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d4e33593434, createdName=caobinglei8090, createdTime=Thu Jan 07 16:35:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380048, encodeId=821d3800481e, content=感觉这个术前没查清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de55206789, createdName=1474f4afm33暂无昵称, createdTime=Wed Mar 04 04:34:58 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515785, encodeId=a6a81515e8564, content=<a href='/topic/show?id=92ace361409' target=_blank style='color:#2F92EE;'>#硬脊膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73614, encryptionId=92ace361409, topicName=硬脊膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70110872610, createdName=ms7421025882867189, createdTime=Fri Feb 14 00:35:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040260, encodeId=256f104026067, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Feb 12 12:35:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=886243, encodeId=6b6288624382, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c305416237, createdName=ms2000001313681173, createdTime=Fri Sep 18 05:14:19 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690788, encodeId=cda21690e88f2, content=<a href='/topic/show?id=de3362880f1' target=_blank style='color:#2F92EE;'>#椎管内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62880, encryptionId=de3362880f1, topicName=椎管内)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6d29130493, createdName=bugit, createdTime=Fri Dec 11 23:35:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724270, encodeId=888c1e24270d4, content=<a href='/topic/show?id=71c1628e901' target=_blank style='color:#2F92EE;'>#椎管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62879, encryptionId=71c1628e901, topicName=椎管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d4e33593434, createdName=caobinglei8090, createdTime=Thu Jan 07 16:35:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380048, encodeId=821d3800481e, content=感觉这个术前没查清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de55206789, createdName=1474f4afm33暂无昵称, createdTime=Wed Mar 04 04:34:58 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515785, encodeId=a6a81515e8564, content=<a href='/topic/show?id=92ace361409' target=_blank style='color:#2F92EE;'>#硬脊膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73614, encryptionId=92ace361409, topicName=硬脊膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70110872610, createdName=ms7421025882867189, createdTime=Fri Feb 14 00:35:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040260, encodeId=256f104026067, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Feb 12 12:35:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-03-04 1474f4afm33暂无昵称

    感觉这个术前没查清楚

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=886243, encodeId=6b6288624382, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c305416237, createdName=ms2000001313681173, createdTime=Fri Sep 18 05:14:19 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690788, encodeId=cda21690e88f2, content=<a href='/topic/show?id=de3362880f1' target=_blank style='color:#2F92EE;'>#椎管内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62880, encryptionId=de3362880f1, topicName=椎管内)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6d29130493, createdName=bugit, createdTime=Fri Dec 11 23:35:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724270, encodeId=888c1e24270d4, content=<a href='/topic/show?id=71c1628e901' target=_blank style='color:#2F92EE;'>#椎管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62879, encryptionId=71c1628e901, topicName=椎管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d4e33593434, createdName=caobinglei8090, createdTime=Thu Jan 07 16:35:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380048, encodeId=821d3800481e, content=感觉这个术前没查清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de55206789, createdName=1474f4afm33暂无昵称, createdTime=Wed Mar 04 04:34:58 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515785, encodeId=a6a81515e8564, content=<a href='/topic/show?id=92ace361409' target=_blank style='color:#2F92EE;'>#硬脊膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73614, encryptionId=92ace361409, topicName=硬脊膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70110872610, createdName=ms7421025882867189, createdTime=Fri Feb 14 00:35:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040260, encodeId=256f104026067, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Feb 12 12:35:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=886243, encodeId=6b6288624382, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c305416237, createdName=ms2000001313681173, createdTime=Fri Sep 18 05:14:19 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690788, encodeId=cda21690e88f2, content=<a href='/topic/show?id=de3362880f1' target=_blank style='color:#2F92EE;'>#椎管内#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62880, encryptionId=de3362880f1, topicName=椎管内)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6d29130493, createdName=bugit, createdTime=Fri Dec 11 23:35:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724270, encodeId=888c1e24270d4, content=<a href='/topic/show?id=71c1628e901' target=_blank style='color:#2F92EE;'>#椎管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62879, encryptionId=71c1628e901, topicName=椎管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d4e33593434, createdName=caobinglei8090, createdTime=Thu Jan 07 16:35:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380048, encodeId=821d3800481e, content=感觉这个术前没查清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de55206789, createdName=1474f4afm33暂无昵称, createdTime=Wed Mar 04 04:34:58 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515785, encodeId=a6a81515e8564, content=<a href='/topic/show?id=92ace361409' target=_blank style='color:#2F92EE;'>#硬脊膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73614, encryptionId=92ace361409, topicName=硬脊膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c70110872610, createdName=ms7421025882867189, createdTime=Fri Feb 14 00:35:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040260, encodeId=256f104026067, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Feb 12 12:35:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-02-12 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关威廉亚洲官网

Cell Death Dis:SKA3通过调节CDK2/P53磷酸化促进肝癌发生发展

纺锤体及着丝粒相关复合物亚基3(SKA3)是纺锤体及着丝粒相关复合物的重要组成成分,对有丝分裂后期的精准进行至关重要。但目前SKA3与肝细胞癌(HCC)之间的关系还尚不清楚。研究人员采用GEO数据库(GSE62232,GSE45436,GSE6764和GSE36376)和TCGA数据库进行分析鉴定差异表达基因。通过CCK8细胞增殖毒性检测实验及平板克隆形成实验分析细胞的增殖能力,而通过划痕实验及小

Cell Death Dis:低氧通过HIF/HEY1/PINK1通路调节肝癌细胞的线粒体活性

缺氧在癌症中很常见。缺氧,由于缺乏氧气(O2)作为电子受体,导致通过线粒体电子传输链的电子转移效率低下,导致活性氧(ROS)积累,从而可能造成不可逆的细胞损伤。通过可引发各种分子事件的缺氧诱导因子1(HIF-1),细胞能够克服低氧。有关由HIF-1调控的新分子机制的知识对于针对缺氧肿瘤的新治疗干预非常重要。研究人员通过肝细胞癌(HCC)模型,发现HIF-1和Notch信号通路通过交叉作用来控制癌细

Gut:浙江大学医学院徐骁教授团队Gut发表肝癌干性研究新成果

近日,国际著名消化杂志Gut在线发表了浙江大学医学院徐骁教授团队的题为USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation的研究论文。

肿瘤组织中某些细胞亚群的 · 2019-12-07

-->

华海清:2019年肝癌内科治疗进展

2019年是不平凡的一年,williamhill asia 的心情跌宕起伏,肝癌免疫治疗的意外失利令williamhill asia 困惑迷茫,而联合治疗的突出效果又使williamhill asia 心潮彭拜,欢欣鼓舞,这一年定会在肝癌的治疗史上绘上浓浓的一笔。 1、PD-1单抗在肝细胞癌(HCC)一、二线治疗中折戟沉沙 纳武单抗(Nivolumab,简称NIVO) 一线治疗HCC出师不利 纳武单抗是PD-1免疫检查点抑制剂,一项I/Ⅱ期的临床研究(CheckMa

静脉注射利多卡因在1例吸毒患者肝癌手术麻醉中的应用

吸毒患者的麻醉选择,既要保证充分的镇痛,保证术中的平稳,又要尽量预防围术期戒断综合征的发生,故合适的麻醉选择显得非常重要。现报道1例静脉注射利多卡因在吸毒患者肝癌手术麻醉中的应用,探讨该类病例麻醉处理方案。

IMbrave 150:III期研究显示肝癌迎来治愈希望

背景 与欧美国家不同,我国肝癌在发病原因、流行病学特征、分子生物学行为、临床表现和分期以及治疗策略上都具有高度异质性。由于早筛早诊不足,约85%的中国患者就诊时已丧失了手术的时机。在现有的诊断、治疗水平下,肝癌患者的5年生存率仅为12.5% 。肝癌治疗目前正面临着极大的未被满足的需求,获得长期生存是患者最迫切的期望。 自索拉非尼在2007年获批成为治疗晚期肝癌一线的标准疗